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Introduction
Venous thromboembolism (VTE) causes significant morbidity, and is the third most common cause of cardiovascular death worldwide [1] . The primary modality of treatment for both pulmonary embolism (PE) and deep vein thrombosis (DVT) is anticoagulant therapy for at least 3 months [2] . In patients with transient or reversible risk factors for VTE that resolve, the risk of recurrent events is relatively low after initial treatment [3] . However, patients with unprovoked events have approximately a 10% risk of recurrent VTE within the first year of stopping treatment [1, 2] . The use of extended-duration anticoagulation (beyond 3-6 months) is associated with a reduction in VTE risk, along with concomitant increases in bleeding events [4] . The use of extended-duration therapy is thus usually limited to those perceived to have a higher risk of recurrent events.
Therapeutic options for VTE have broadened over the last 10 years with the approval of direct oral anticoagulants (DOACs) [5] [6] [7] [8] [9] . DOACs are associated with a reduced rate of bleeding events as compared with oral vitamin K antagonists (VKAs) [4] . DOACs are attractive options for patients and providers, given the lack of need for regular laboratory monitoring, fixed dosing, and the infrequency of drug-drug or drug-food interactions.
More recently, there have been studies addressing the period after the 'acute phase' of VTE treatment. The spectrum of therapeutic options ranges from cessation of treatment to continuation of full-dose anticoagulation. Antiplatelet agents such as aspirin have also been used in extended-duration VTE treatment in an effort to mitigate bleeding risks, but they are only somewhat more effective than placebo [4, 10] . Similarly, reduced-dose warfarin has been tested and proven to be unsatisfactory in this setting [11] . The use of reduced-dose DOACs has been studied in randomized controlled trials, and may effectively balance the concerns of recurrent thrombosis and risk of bleeding in the extended phase of VTE treatment, when the risk of recurrent VTE declines [12, 13] .
To our knowledge, the efficacy of reduced-dose DOACs has not been systematically reviewed; we therefore conducted a systematic review and meta-analysis to compare the efficacy of reduced-dose DOACs with that of full-dose anticoagulation and no anticoagulation (antiplatelet or placebo) in the extended phase of VTE treatment. We examined the impact of reduced-dose DOACs on the prevention of recurrent VTE and major or clinically relevant non-major bleeding events. Our goal was to provide treating physicians with guidance on the use of these medications in day-to-day clinical practice.
Methods

Eligibility criteria
We included randomized controlled trials involving adults (aged ≥ 18 years) with VTE (DVT or PE) after the completion of at least 3 months and no more than 12 months of acute treatment with any anticoagulant, in whom stopping anticoagulation could be considered. The included studies must have included one or both of a group treated with full-dose anticoagulation (of any type) and a control group treated with no anticoagulation; these groups were compared with a reduced-dose DOAC group. The control group could include treatment with antiplatelet agents or placebo. The studies must have followed both recurrent VTE and bleeding events. Studies were excluded if they used anticoagulants not currently approved for the treatment of VTE.
Search strategy
We searched for titles in the MEDLINE, EMBASE and CINAHL databases up to April 2017. Relevant conference abstracts from the ISTH and American Society of Hematology were hand-searched. A review of reference lists from retrieved titles was conducted. There were no language-based restrictions. As an example, PubMed was used to access the MEDLINE database, and the search was constructed as a mix of MeSH and plain search terms to identify citations of randomized trials using DOACs in the extended treatment of VTE (Data S1).
Study selection and data extraction
Screening of titles and abstracts for eligibility was performed independently by two reviewers (L.V. and K.B.) in duplicate. The full texts of articles found to be potentially eligible were screened by the two independent reviewers. Conflicts were addressed by consensus involving consultation with the other authors. If data from a single trial were presented in multiple publications, secondary publications were also utilized for data extraction. A flow diagram of the search protocol is reported according to the PRISMA model [14] .
Data were extracted independently by two authors in duplicate (L.V. and K.B.). The final entered data were compared, and discrepancies were addressed by article review and consensus. The study characteristics extracted included elements of study design and baseline patient characteristics including age, gender, weight, type (provoked or unprovoked) and location (DVT or PE) of the index event, the method used for acute anticoagulation, renal function as estimated by creatinine clearance (CrCl), the presence of active cancer, and prior VTE. Accepted studies were evaluated with the Cochrane Collaboration's tool for assessing risk of bias in randomized trials [15] .
Outcomes
Our primary outcome of interest was recurrent VTE, including VTE-related mortality. Bleeding outcomes were also assessed in the form of major bleeding events according to the ISTH definition, and clinically relevant nonmajor bleeding events were assessed as individually defined by the studies. Outcomes from prespecified subgroups of interest, such as stratifications by age (< 65 years, 65-75 years, and > 75 years) and kidney function (CrCl of < 50, 50-80, and > 80), were also collected. The quality of evidence for each outcome across studies was assessed with the Grading of Recommendation Assessment Development and Evaluation (GRADE) method by use of the GRADEpro Guideline Development Tool (McMaster University, 2015) [16] .
Data synthesis and analysis
All analyses were performed with REVIEW MANAGER (Version 5.3.5, Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration, 2014). Pooled direct comparisons were made between reduced-dose DOAC and full-dose anticoagulant, and between reduced-dose DOAC and no anticoagulant. Outcomes were assessed and presented as pooled risk ratios (RRs) by use of the MantelHaenszel random effects model along with 95% confidence intervals (CIs). The absolute risk reduction (ARR) and the risk difference were calculated for each outcome. P-values of < 0.05 were considered to be statistically significant. Heterogeneity of data was assessed with Cochrane's Q statistic and the I 2 statistic. A priori subgroups planned for analyses included age (< 65 years, 65-75 years, and > 75 years) and renal function (CrCl of < 50, 50-80, and > 80). A sensitivity analysis was undertaken with the fixed effects model in lieu of the random effects model.
Results
The literature search was completed in March 2017, and retrieved 1399 unique citations. The full text of 17 articles and abstracts were reviewed, and ultimately two met the criteria for inclusion (Fig. 1) .
Study characteristics and risk of bias assessment
Both of the included studies were multicenter randomized trials whose study designs and key characteristics are compared in Table 1 . Both studies involved patients treated acutely for VTE for 6-12 months prior to randomization. The AMPLIFY-EXT trial by Agnelli et al. [12] had three treatment arms: full-dose anticoagulation with apixaban 5 mg twice daily, reduced-dose treatment with apixaban 2.5 mg twice daily, and no anticoagulation with placebo. The EINSTEIN CHOICE trial by Weitz et al.
[13] also had three treatment arms: full-dose anticoagulation with rivaroxaban 20 mg daily, reduced-dose treatment with rivaroxaban 10 mg daily, and no anticoagulation with low-dose aspirin 81 mg daily. Both studies aimed to follow patients for 1 year after randomization. The primary outcome of both studies was recurrent symptomatic VTE, defined as DVT and fatal or non-fatal PE. The two studies also used similar definitions to characterize major bleeding events: a reduction in the hemoglobin level of ≥ 2 g dL -1 , transfusion of ≥2 units of red cells, bleeding into a critical site, or fatal bleeding. Clinically relevant non-major bleeding was broadly defined in the EINSTEIN CHOICE study as any event necessitating the cessation of the study drug for > 2 weeks, and in the AMPLIFY-EXT trial as a variety of more specific conditions, including a functionally impairing bleed, bleeding in 'high-risk' sites, and bleeding requiring a visit to a physician or temporary cessation of the study drug [12, 13] . The studies were assessed with the Cochrane risk of bias tool (Fig. 2) . Both studies were randomized with concealed allocation, and had participants, healthcare providers and outcome assessors blinded to treatment group. Data were reported for all prespecified outcomes. In combination, 5847 patients were analyzed for recurrent VTE (2482 in the AMPLIFY-EXT trial and 3365 in the EINSTEIN CHOICE trial) and 5842 were analyzed for bleeding events (2477 in the AMPLIFY-EXT trial and 3365 in the EINSTEIN CHOICE trial). Twenty-four patients were lost to follow-up (14 in the AMPLIFY-EXT trial and 10 in the EINSTEIN CHOICE trial).
A decision was made to proceed with a meta-analysis in spite of the small number of identified studies, as the studies were very similar in design. A combination of patients from the two similar studies would allow the results of the meta-analysis to offer greater precision than the individual studies.
Recurrent VTE
Both studies were included in this analysis. There was no difference between reduced-dose DOAC (31/1967 = 1.6%) and full-dose anticoagulation (27/1920 = 1.4%) in the risk of recurrent VTE (RR 1.12, 95% CI 0.67-1.87; ARR 2 more per 1000, 95% CI À 5 to + 12 per 1000; P for heterogeneity of 0.59; Fig. 3 ). As compared with aspirin or placebo, with which the risk of recurrence was 123 of 1960 (6.3%), the risk of recurrent VTE was significantly decreased with reduced-dose DOAC (RR 0.26, 95% CI 0.14-0.46; ARR 46 fewer per 1000, 95-% CI À 54 to À 34; P for heterogeneity of 0.14; Fig. 4) . A separate analysis showed that full-dose DOAC treatment resulted in significantly fewer recurrent events than aspirin or placebo (RR 0.23, 95% CI 0.15-0.34). The results were unchanged when we performed subgroup analyses according to age and renal function (data not shown). A sensitivity analysis showed that the results were unchanged when the fixed effects model was used (data not shown). The quality of evidence was moderate for the comparison between reduced-dose DOAC and full-dose DOAC, being graded down because of imprecision ( Table 2 ). The quality of evidence was moderate to high for the comparison between reduced-dose DOAC and aspirin or placebo, also being graded down because of imprecision (Table 2) .
Bleeding events
Reduced-dose DOAC (54/1967 = 2.7%) did not show a difference in major or clinically relevant non-major bleeding from full-dose anticoagulation (71/1920 = 3.7%) (RR 0.74, 95% CI 0.52-1.05; ARR 10 fewer per 1000, 95% CI À 18 to + 2; P for heterogeneity of 0.97; Fig. 5 ) or aspirin or placebo (45/1960 = 2.3%) (RR 1.19, 95% CI 0.81-1.77; ARR 4 more per 1000, 95% CI À 4 to + 18; P for heterogeneity of 0.94; Fig. 6 ). A separate analysis showed that full-dose DOAC treatment did lead to significantly more bleeding than aspirin or placebo (RR 1.61, 95% CI 1.11-2.33). The results were again unchanged after subgroup analyses according to age and renal function (data not shown). Analysis with the fixed effects model did not affect the nature of the results (data not shown). The quality of evidence was moderate for both comparisons, being graded down because of imprecision (Table 2) .
Mortality
Death occurred infrequently in the two studies. There were four VTE-related deaths and two bleeding-related deaths in the EINSTEIN CHOICE trial, and no deaths of either type in the AMPLIFY-EXT trial. 
Discussion
Our systematic review of the extended phase of anticoagulation in VTE suggests that reduced-dose DOACs are as effective in preventing recurrent thrombotic events at 1 year as full-dose DOACs, with a rate of major bleeding events that is comparable to that with aspirin or placebo. The quality of evidence for both outcomes -recurrent VTE and bleeding events -was moderate to high. The use of reduced-dose DOACs in this setting has similar efficacy to full-dose treatment with regard to recurrent VTE, but, unlike full-dose treatment, did not cause a significant increase in bleeding as compared with aspirin or placebo.
The strengths of our study include the high quality of the included studies, both being large, multicenter, welldesigned randomized controlled trials at low risk of bias. In addition to rigorous designs, the two trials had common definitions of endpoints and follow-up time, allowing justifiable pooling of the data for analysis. In addition, there was no significant heterogeneity in any outcome analyzed. Although follow-up in the trial setting was probably more rigorous than in standard practice, the inclusion and exclusion criteria of the study were broad, suggesting that the results are generalizable to patients with a first instance of VTE without major medical comorbidities.
The limitations of this review include the paucity of studies utilizing reduced-dose DOAC anticoagulation in the extended treatment of VTE. Only two relevant studies were retrieved in our search, representing two of four DOACs that have been approved for the acute treatment Total (95% CI) Total events Heterogeneity: Tau of VTE. It is unclear at this point whether this represents a class effect for DOACs, or whether the results are applicable only to apixaban and rivaroxaban. The control group also differed between the studies: placebo was used in the apixaban trial, and aspirin in the rivaroxaban trial. Both studies followed patients for only 1 year after acute VTE treatment -thus, the safety and efficacy of reduceddose DOAC is unknown beyond 1 year. Some clinicians may use the available data to utilize low-dose DOACs indefinitely in patients; however, currently, neither the safety nor the efficacy of this strategy has been proven. Conclusions about the bleeding profile of low-dose DOACs must be tempered by the limitations of the study designs, and require further dedicated studies. Eligibility for both studies was limited to patients in whom there was equipoise regarding continuing anticoagulation, and included patients with either unprovoked or provoked VTE. Current expert opinion suggests the consideration of continued anticoagulation for those with unprovoked VTE in the absence of major contraindications, as well as stopping anticoagulation for those with provoked VTE [2] . In addition, the results are not generalizable to groups that were not included or were underrepresented in the trials. Specifically, patients with an ongoing indication for anticoagulation (e.g. active cancer or recurrent VTE) were not included, and these patients should continue to be treated with 'usual-intensity therapy'. Finally, there were very few patients with a weight of > 120 kg enrolled in the studies, and current expert opinion suggests that the use of DOACs should be avoided in this population [17] .
The optimal duration of anticoagulation after an episode of VTE remains controversial. Premature discontinuation of anticoagulation results in avoidable thromboembolism, whereas continuing anticoagulation beyond the period of highest risk of VTE results in avoidable bleeding. Our review, however, suggests that reduced-dose anticoagulation with DOACs leads to a significant reduction in the rate of recurrent VTE, without a major increase in the rate of bleeding at 1 year. It is of note that the EINSTEIN CHOICE trial included a large proportion of patients with provoked VTE, in contrast to the AMPLIFY-EXT trial. Patients with provoked VTE would be expected to have a reduced likelihood of recurrence, but, in both the EINSTEIN CHOICE trial and our meta-analysis, reduced-dose DOACs still led to significantly fewer recurrent VTE events. This opens the possibility of continuing reduced-dose anticoagulation even in those thought to have too low a thrombotic risk to continue with full-dose anticoagulation. Morbid outcomes (death and major or life-threatening bleeding) were uncommon in the contributing studies, reflecting the relatively young age and freedom from major comorbidities of patients with VTE as compared with patients with other indications for DOACs.
Our results suggest that reduced-dose DOACs may be an attractive option for extended phase anticoagulation after VTE in patients in whom there is equipoise with respect to the continuation of anticoagulation, but further studies are needed to characterize the safety of this therapy, particularly beyond 1 year. Patients can be confident that dose reduction does not increase their risk of thrombosis after the acute treatment phase. The risk of major bleeding with reduced-dose DOACs appears to be similar to that with aspirin or no anticoagulation, but larger dedicated studies are needed before this effect can be Test for overall effect: Z = 0.89 (P = 0.37) considered to be conclusive. Additional studies are also needed in patients with an indication for ongoing anticoagulant therapy, to assess whether empirical dose reduction is an effective treatment strategy after an initial period of usual-intensity therapy. 
